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Table S1. Association between mercury exposure and ANA positivity among females 16-49 years in the
general US population (NHANES), with adjustment for polychlorinated biphenyls (PCBs).
Mercury exposure ANA positive
n (%)a 
Crude Modelb 
OR (95% CI)
Coplanar PCBsc,d
OR (95% CI) 
Prevalent PCBsc,e
OR (95% CI) 
Hair mercury (ppm)f
Tertile 1 (<0.11) 13 (8) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Tertile 2 (0.11-0.27) 22 (13) 1.61 (0.27, 9.64) 2.71 (0.54, 13.55) 2.65 (0.57, 12.30)
Tertile 3 (0.271-5.96) 20 (15) 1.96 (0.57, 6.77) 4.44 (1.60, 12.28) 4.03 (1.65, 9.84)
Total blood mercury (µg/L)g
Quartile 1 (<0.4) 27 (9) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Quartile 2 (0.4-0.8) 67 (21) 2.52 (1.16, 5.47) 2.70 (1.29, 5.67) 2.30 (1.11, 4.78)
Quartile 3 (0.9-1.5) 50 (17) 2.04 (0.95, 4.39) 2.43 (1.12, 5.27) 2.07 (0.97, 4.42)
Quartile 4 (1.6-32.8) 61 (18) 2.10 (0.98, 4.50) 2.71 (1.25, 5.86) 2.33 (1.09, 4.98)
Abbreviations: ANA, antinuclear antibody; PCBs, polychlorinated biphenyls; Hg, mercury; NHANES, National
Health and Nutrition Examination Survey; OR, odds ratio.
aWeighted percent. bModels include subset with available PCB data (samples size reduced by ~6% compared to main
analyses). cAdjusted for age, race/ethnicity, education, serum cotinine, selenium, omega-3 fatty acids, and an indicator
for NHANES cycle for models combining data across cycles (1999-2004). dCoplanar (dioxin-like) PCB congeners
included PCBs (81, 105, 118, 126, 156, 157, 167, 169); a summary measure was calculated as the sum of the products
of the concentration of each serum lipid-adjusted congener and its corresponding toxic equivalency factor (TEF),
which was then log-transformed. eThe Prevalent PCB measure is the log-transformed sum of the lipid-adjusted values
for the four most prevalent PCB congeners (PCBs 118, 138, 153, 180), three of which are non-coplanar and without
defined TEFs to take into account. fNHANES 1999-2000, 1 cycle (n=424). gNHANES 1999-2004, 3 cycles (n=1281).
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Table S2. Association between mercury exposure and ANA titer strength, among females 16-49 years in the
general US population (NHANES), based on multinomial logistic regression modeling.
Mercury exposure ANA positive
n (%)a 
Crude Model
OR (95% CI)
Model Ab
OR (95% CI) 
Model Bc
OR (95% CI) 
Model Cd
OR (95% CI) 
Hair mercury (ppm)e
ANA negative (n=396) NA NA NA NA NA
ANA 1:80-1:640 (n=32)
Tertile 1 (<0.11) 11 (7) 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Tertile 2 (0.11-0.27) 9 (2) 0.23 (0.03, 2.04) 0.23 (0.04, 1.32) 0.24 (0.04, 1.38) 0.20 (0.02, 1.64)
Tertile 3 ( 0.271-5.96) 12 (6) 0.82 (0.40, 1.69) 2.93 (1.22, 7.06) 2.98 (1.29, 6.90) 2.11 (0.73, 6.15)
ANA ≥1:1280 (n=24)
Tertile 1 (<0.11) 3 (1) 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Tertile 2 (0.11-0.27) 13 (11) 11.81 (0.98, 142.86) 13.74 (1.09, 172.78) 16.69 (1.63, 171.23) 14.29 (1.02, 200.25)
Tertile 3 (0.271-5.96) 8 (8) 9.47 (1.43, 62.60) 11.14 (1.53, 81.36) 11.41 (1.60, 81.23) 12.57 (1.36, 116.44)
Total blood mercury (µg/L)f
ANA negative (n=1139) NA NA NA NA NA
ANA 1:80-1:640 (n=109)
Quartile 1 (<0.4) 20 (8) 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Quartile 2 (0.4-0.8) 40 (11) 1.55 (0.66, 3.62) 1.61 (0.64, 4.10) 1.62 (0.64, 4.09) 1.63 (0.59, 4.55)
Quartile 3 (0.9-1.5) 23 (8) 1.06 (0.46, 2.42) 1.37 (0.56, 3.38) 1.39 (0.57, 3.36) 1.27 (0.45, 3.55)
Quartile 4 (1.6-32.8) 26 (6) 0.82 (0.40, 1.70) 1.10 (0.45, 2.70) 1.11 (0.46, 2.69) 1.09 (0.35, 3.41)
ANA ≥1:1280 (n=104)
Quartile 1 (<0.4) 10 (2) 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Quartile 2 (0.4-0.8) 31 (9) 4.70 (1.30, 16.98) 4.23 (1.10, 16.24) 4.20 (1.09, 16.24) 4.42 (1.15, 16.99)
Quartile 3 (0.9-1.5) 28 (8) 4.35 (1.27, 14.82) 4.21 (1.18, 15.09) 4.13 (1.15, 14.80) 4.57 (1.26, 16.60)
Quartile 4 (1.6-32.8) 35 (11) 5.91 (1.70, 20.56) 6.04 (1.59, 22.86) 5.93 (1.57, 22.47) 6.17 (1.61, 23.70)
Abbreviations: ANA, antinuclear antibody; Hg, mercury; NHANES, National Health and Nutrition Examination
Survey; OR, odds ratio
aWeighted percent. bAdjusted for age, race/ethnicity, education, serum cotinine, selenium, and an indicator for
NHANES cycle for multi-cycle models. cModel A + further adjusted for omega-3 fatty acids. dModel A + further
adjusted for total seafood intake. eNHANES 1999-2000, 1 cycle (n=452). fNHANES 1999-2004, 3 cycles (n=1352).
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